1
|
Siebenhuener K, Eschmann E, Kienast A, Schneider D, Minder CE, Saller R, Zimmerli L, Blaser J, Battegay E, Holzer BM. Chronic Pain: How Challenging Are DDIs in the Analgesic Treatment of Inpatients with Multiple Chronic Conditions? PLoS One 2017; 12:e0168987. [PMID: 28046033 PMCID: PMC5207693 DOI: 10.1371/journal.pone.0168987] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2016] [Accepted: 12/10/2016] [Indexed: 11/25/2022] Open
Abstract
Background Chronic pain is common in multimorbid patients. However, little is known about the implications of chronic pain and analgesic treatment on multimorbid patients. This study aimed to assess chronic pain therapy with regard to the interaction potential in a sample of inpatients with multiple chronic conditions. Methods and Findings We conducted a retrospective study with all multimorbid inpatients aged ≥18 years admitted to the Department of Internal Medicine of University Hospital Zurich in 2011 (n = 1,039 patients). Data were extracted from the electronic health records and reviewed. We identified 433 hospitalizations of patients with chronic pain and analyzed their combinations of chronic conditions (multimorbidity). We then classified all analgesic prescriptions according to the World Health Organization (WHO) analgesic ladder. Furthermore, we used a Swiss drug-drug interactions knowledge base to identify potential interactions between opioids and other drug classes, in particular coanalgesics and other concomitant drugs. Chronic pain was present in 38% of patients with multimorbidity. On average, patients with chronic pain were aged 65.7 years and had a mean number of 6.6 diagnoses. Hypertension was the most common chronic condition. Chronic back pain was the most common painful condition. Almost 90% of patients were exposed to polypharmacotherapy. Of the chronic pain patients, 71.1% received opioids for moderate to severe pain, 43.4% received coanalgesics. We identified 3,186 potential drug-drug interactions, with 17% classified between analgesics (without coanalgesics). Conclusions Analgesic drugs-related DDIs, in particular opioids, in multimorbid patients are often complex and difficult to assess by using DDI knowledge bases alone. Drug-multimorbidity interactions are not sufficiently investigated and understood. Today, the scientific literature is scarce for chronic pain in combination with multiple coexisting medical conditions and medication regimens. Our work may provide useful information to enable further investigations in multimorbidity research within the scope of potential interactions and chronic pain.
Collapse
Affiliation(s)
- Klarissa Siebenhuener
- Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
- Center of Competence Multimorbidity, University of Zurich, Zurich, Switzerland
| | - Emmanuel Eschmann
- Research Center for Medical Informatics, Directorate of Research and Education, University Hospital Zurich, Zurich, Switzerland
| | - Alexander Kienast
- Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
| | - Dominik Schneider
- Maennedorf Hospital, Department of Internal Medicine, Canton Zurich, Switzerland
| | | | - Reinhard Saller
- Center of Competence Multimorbidity, University of Zurich, Zurich, Switzerland
- Institute of Complementary and Integrative Medicine, University Hospital Zurich, Zurich, Switzerland
| | - Lukas Zimmerli
- Center of Competence Multimorbidity, University of Zurich, Zurich, Switzerland
- Cantonal Hospital, Internal Medicine, Olten, Switzerland
| | - Jürg Blaser
- Research Center for Medical Informatics, Directorate of Research and Education, University Hospital Zurich, Zurich, Switzerland
| | - Edouard Battegay
- Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
- Center of Competence Multimorbidity, University of Zurich, Zurich, Switzerland
- University Research Priority Program ‘Dynamics of Healthy Aging,’ University of Zurich, Zurich, Switzerland
| | - Barbara M. Holzer
- Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
- Center of Competence Multimorbidity, University of Zurich, Zurich, Switzerland
- * E-mail:
| |
Collapse
|
2
|
Samer CF, Dayer P, Desmeules JA. How close are we to individual analgesic adjustment according to a patient’s genotype? Per Med 2011; 8:289-292. [DOI: 10.2217/pme.11.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- Caroline Flora Samer
- Clinical Pharmacology & Toxicology, Geneva University Hospitals, Switzerland and Swiss Center for Applied Human Toxicology, University of Geneva, Switzerland
| | - Pierre Dayer
- Clinical Pharmacology & Toxicology, Geneva University Hospitals, Switzerland
| | - Jules Alexandre Desmeules
- Clinical Pharmacology & Toxicology Geneva University Hospitals Rue Gabrielle-Perret-Gentil 4, 1211 Geneva 14, Switzerland and Swiss Center for Applied Human Toxicology, University of Geneva, Switzerland
| |
Collapse
|
3
|
Abstract
Since the first draft of the human genome was published 10 years ago, scientists have tried to develop new treatment strategies for various types of diseases based on individual genomes. It is called personalized (or individualized) medicine and is expected to increase efficacy and reduce adverse reactions of drugs. Much progress has been made with newly developed technologies, though individualized pain medicine is still far from realization. Efforts on the integrative genomic analyses along with understandings of interactions between other related factors such as environment will eventually translate complex genomic information into individualized pain medicine.
Collapse
|